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We previously reported that camostat mesilate (CM) had renoprotective and antihypertensive effects in
rat CKD models. In this study, we examined if CM has a distinct renoprotective effect from telmisartan
(TE), a renin-angiotensin-aldosterone system (RAS) inhibitor, on the progression of CKD. We evaluated
the effect of CM (400 mg/kg/day) and/or TE (10 mg/kg/day) on renal function, oxidative stress, renal
ﬁbrosis, and RAS components in the adenine-induced rat CKD model following 5-weeks treatment
period. The combination therapy with CM and TE signiﬁcantly decreased the adenine-induced increase
in serum creatinine levels compared with each monotherapy, although all treatment groups showed
similar reduction in blood pressure. Similarly, adenine-induced elevation in oxidative stress markers and
renal ﬁbrosis markers were signiﬁcantly reduced by the combination therapy relative to each mono-
therapy. Furthermore, the effect of the combination therapy on plasma renin activity (PRA) and plasma
aldosterone concentration (PAC) was similar to that of TE monotherapy, and CM had no effect on both
PRA and PAC, suggesting that CM has a distinct pharmacological property from RAS inhibition. Our
ﬁndings indicate that CM could be a candidate drug for an add-on therapy for CKD patients who had
been treated with RAS inhibitors.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertension and proteinuria have been recognized as two
major risk factors for the progression of CKD. Conversely, the efﬁ-
cacy of antihypertensive drugs having renoprotective effect by the
suppression of proteinuria, especially inhibitors of the renin-
angiotensin-aldosterone system (RAS) has been proven in a num-
ber of clinical trials (1e3), and RAS inhibitors are becoming one ofrnal Medicine, University of
09-3898, Japan. Tel.: þ81 55
itamura).
rmacological Society.
. Production and hosting by Elsethe few therapeutic drugs to prevent the progression of CKD.
However, RAS inhibitors can only partially prevent the progression
of CKD, and patients still show some progression of renal failure
(4e6). To take full advantage of RAS inhibitors and fully prevent the
progression of CKD, the development of an additional treatment is
urgently needed.
In Japan, camostat mesilate (CM), an orally active synthetic
serine protease inhibitor, has been clinically used for the treatment
of chronic pancreatitis and postgastrectomy reﬂux esophagitis, and
its clinical safety has already been established. CM has been re-
ported not only to inhibit various serine proteases, but also to
reduce proteinuria in both experimental and clinical glomerulo-
nephritis (7e9). We previously demonstrated that CM had a
renoprotective effect due to its natriuretic effect through thevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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epithelial sodium channel in the kidney (9). Subsequent studies
fromour laboratory clearly showed the renoprotective effects of CM
through the suppression of proteinuria, oxidative stress, inﬂam-
mation, and renal ﬁbrosis independently of its blood pressure-
lowering effect (10). In particular, CM attenuated oxidative stress
by decreasing the expression of NADPH oxidase components and
reduced renal ﬁbrosis by inhibiting TGF-b1 signaling (10, 11).
Furthermore, we recently reported that CM has a potent direct
radical scavenging activity independently of its inhibitory effect
against serine proteases (12). These ﬁndings suggest the possibility
that serine protease(s) is/are involved in the progression of CKD.
Although the renoprotective effect of CM has been shown by the
previous studies described above, the effect of CM on RAS com-
ponents has not been studied before. Moreover, it has not been
investigated whether CM can provide an additional renoprotection
on RAS inhibitors in the progression of CKD. Therefore, in the cur-
rent studies, we examined if the renoprotective effect of CM de-
pends on the RAS signaling and if CM could provide an additional
beneﬁt when combined with RAS inhibitors in a rat CKD model.
2. Materials and methods
2.1. Materials
CM was a kind gift from Ono Pharmaceutical Co., Ltd. (Osaka,
Japan). TE was purchased as Micardis® Tablet from Astellas Pharma
Inc. (Tokyo, Japan). Hydralazine (HYD) was purchased from Sig-
maeAldrich (St. Louis, Mo., USA). Adenine and methylcellulose 400
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). All other chemicals were of the highest grade available from
commercial sources.
2.2. Administration of CM and/or TE on the adenine-induced rat
CKD model
All animal procedures were in accordance with the guidelines
for care and use of laboratory animals approved by Kumamoto
University. Thirteen-week-old male Sprague-Dawley rats (Japan
SLC, Inc., Shizuoka, Japan) were used in this study. All rats were
housed under controlled humidity, temperature, a 12:12-h light-
dark cycle, and direct access to standard chow and tap water.
The adenine-induced rat CKDmodel was prepared following the
established method (13). After having conﬁrmed that serum
creatinine levels were increased to approximately 4 mg/dL, the rats
were divided into 6 groups; 1) control group (n ¼ 8), 2) CKD group
(adenine-induced CKD, n ¼ 8), 3) TE group (adenine-induced
CKDþTE, n¼ 8), 4) CM group (adenine-induced CKDþCM, n¼ 8), 5)
CMþTE group (adenine-induced CKDþCM and TE, n ¼ 6) and 6)
HYD group (adenine-induced CKDþHYD, n ¼ 6). CM (400 mg/kg/
day)was suspended in distilled water and administered twice a day
via oral gavage as previously described (12). Similarly, TE (10 mg/
kg/day) was suspended in 0.5% methylcellulose 400 and adminis-
tered twice a day via oral gavage. The doses of CM and TE were
determined to havemaximum renoprotective effect on rat remnant
kidney model based on previous reports (12, 14). Because we found
that the combination therapy with CM and TE showed greater
reduction in SBP than each monotherapy in preliminary experi-
ments, we arranged a CKD group which was treated by HYD to a
similar SBP level with CMþTE. In our current study, HYD was
administered via drinking water at a dose of 10 mg/kg/day. At the
end of the study period, all rats were weighed, and systolic blood
pressure (SBP) was measured by the tail-cuff method using a BP-
98E manometer (Softron Co., Ltd., Tokyo, Japan). Twenty-four
hour urine collections were made in metabolic cages and volume,electrolytes, and creatinine were measured. After a 5-week treat-
ment period, the rats were anesthetized with an intraperitoneal
injection of pentobarbital sodium (40 mg/kg) and blood samples
and kidneyswere collected. Creatinine and electrolytes in the blood
were measured by a commercial laboratory (SRL, Tokyo, Japan) and
kidneys were weighed and sliced into thin sections.2.3. Histological studies
Resected kidneys were ﬁxed with Dubosq-Brazil Fixative and
embedded in parafﬁn. Embedded Kidney samples were sectioned
at thicknesses of 2-mm and stained with periodic acid-Schiff (PAS)
and Azan-Mallory. Azan-Mallory stained sections were photo-
graphed, and ten pictures were selected at random for histological
analysis. The extent of interstitial ﬁbrosis was estimated fromAzan-
Mallory stained sections. The ﬁbrotic area was measured as the
percentage of blue collagen staining in the tubulointerstitium with
the exception of the tubular lumens and vessel walls using the
Hybrid Cell Count image analysis (Keyence All-in-One Microscope
BZ-X700, Osaka, Japan). The reactive oxygen species (ROS) pro-
duction in the kidney was evaluated by dihydroethidium (DHE)
staining as previously described (10), and images were captured by
an Olympus BX50 with BH2-RFL-T3 (Olympus, Tokyo, Japan).
Quantiﬁcation of ﬂuorescence intensity was determined by using
Image-J (National Institutes of Health, Bethesda, MD, USA).2.4. Real-time polymerase chain reaction (PCR)
Whole kidney total RNA was extracted with SV Total RNA
Isolation Kit (Promega, Madison, MI), and 1 mg of total RNA was
transcribed with Prime Script RT Master Mix kit (Takara Bio, Otsu,
Japan). TaqMan probe for a-smooth muscle actin (a-SMA), plas-
minogen activator inhibitor-1 (PAI-1), and connective tissue growth
factor (CTGF) and 28S ribosomal RNAwere purchased from Applied
Biosystems (Foster City, CA, USA). Real-time PCR was performed
with a Light Cycler 480 (Roche Applied Science, Indianapolis, IN,
USA). Statistical analysis of results was performed with the DCt
(threshold cycle) value (Ct gene of interest  Ct 28S ribosomal RNA).
Relative gene expression was obtained from the DDCt method
(Ctsample  Ctcalibrator).2.5. Advanced oxidative protein products (AOPPs)
Plasma levels of AOPPs were determined by a protocol based on
the method of Witko-Sarsat et al. (15). AOPPs concentrations were
expressed in micromoles per liter of chloramine-T equivalents.2.6. 2 e thiobarbituric acid reactive substances (TBARS)
Plasma levels of TBARS were measured by using a TBARS assay
kit (JaICA, Shizuoka, Japan). TBARS concentrations were expressed
in micromoles per liter of malondialdehyde (MDA) equivalents.2.7. Immunoblot analysis
Pieces of kidney cortex were homogenized in ice-cold signal
detection buffer. Aliquots of homogenized sample containing 30 mg
of proteins were subjected to SDS-PAGE and transferred onto a
polyvinylidene ﬂuoride membrane. After being blocked with 5%
skimmed milk powder in TBS-T, blots were probed with mono-
clonal antibodies against a-SMA (1:1,000, Dako, Glostrup,
Denmark), ﬁbronectin (1:10,000, SigmaeAldrich, St. Louis, MO),
and GAPDH (1:1,000, Cell Signaling Technology, Danvers, MA).
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Results are expressed as means ± SE. Comparisons were made
using ANOVA followed by the Newman-Keuls method for multiple
comparisons. P values < 0.05 were considered as statistically sig-
niﬁcant. All statistical analyses were performed with the aid of
GraphPad PRISM (GraphPad Software, La Jolla, CA).Fig. 1. Effect of CM and/or TE treatment on systolic blood pressure. At the end
of the study period, systolic blood pressure (SBP) was measured by the tail-cuff
method. Results are expressed as means ± SE. *P < 0.05, **P < 0.01, ***P < 0.001
compared with the Control group; #P < 0.05, ###P < 0.001 compared with the
CKD group.3. Results
3.1. Effect of CM and/or TE treatment on general parameters
After 3 weeks of adenine administration, all ﬁve groups devel-
oped CKD as assessed by serum creatinine levels. The ﬁve CKD
groups showed a decrease in body weight and creatinine clearance,
and an increase in urinary volume and urinary sodium/potassium
excretion ratio when compared with the control group, but there
were no other statistically signiﬁcant differences (Table 1). Serum
creatinine levels were markedly elevated in the ﬁve CKD groups
compared to the control group, and treatment groups except for the
HYD group had decreased serum creatinine levels. Importantly,
combination therapy with CM and TE resulted in a greater reduc-
tion in the serum creatinine levels compared with each mono-
therapy. Adenine administration markedly increased kidney
weight in the ﬁve CKD groups, whereas treatment groups except for
the HYD group demonstrated a signiﬁcant decrease relative to the
CKD group. Adenine-induced increase in serum potassium levels
were signiﬁcantly reduced in both CM group and CMþTE group,
and no signiﬁcant difference was observed between the two
groups.3.2. Effect of CM and/or TE treatment on systolic blood pressure
Fig. 1 shows the change in SBP at the end of the study period. No
signiﬁcant differences were observed in SBP between the control
group and the CKD group. All treatment groups reduced SBP levels.
The combination therapy group and the HYD group showed a
further reduction in SBP to a similar extent, but there were no
statistically signiﬁcant differences between the combination ther-
apy and each monotherapy.3.3. Effect of CM and/or TE treatment on renal morphology
Kidneys from the ﬁve CKD groups showed marked renal
swelling, discoloration, and deformity as compared with those
from the control group. Treatment groups except for the HYD group
attenuated gross morphologic injury, while combination therapyTable 1
Data at the end of the experiment.
Control CKD TE
n 8 8 8
BW (g) 500 ± 6 376 ± 20*** 388 ± 13***
KW/BW (mg/g) 11.1 ± 0.4 83.2 ± 7.7*** 52.2 ± 4.3***,##
UV (mL/day) 22 ± 1.3 80 ± 4.8*** 81 ± 3.8***
Cre (mg/dL) 0.26 ± 0.01 2.01 ± 0.12*** 1.55 ± 0.03***,##
Ccr (mL/min/kg) 7.61 ± 0.51 0.69 ± 0.1*** 1.26 ± 0.06***
Na (meq/L) 144 ± 1 143 ± 1 142 ± 1
K (meq/L) 3.9 ± 0.1 6.0 ± 0.1***,zz 5.6 ± 0.2***,z
U-Na/K 0.48 ± 0.02 0.58 ± 0.01* 0.57 ± 0.02*
Results are expressed as means ± SE. CKD: chronic kidney disease, TE: telmisartan, CM: ca
weight, UV: urine volume, Cre: serum creatinine, Ccr: creatinine clearance, Na: serum sod
**P < 0.01, ***P < 0.001 compared with Control group; #P < 0.05, ##P < 0.01, ###P < 0.00
compared with CM group; xP < 0.05, xxxP < 0.001 compared with HYD group.further ameliorated morphologic injury beyond the effect of each
monotherapy (Fig. 2).3.4. Effect of CM and/or TE treatment on renal histology
Changes in renal histology were determined by PAS staining
and Azan-Mallory staining of kidney sections. On PAS staining,
no signiﬁcant differences were observed in glomeruli among
the six groups (Fig. 3A), but severe interstitial ﬁbrosis with
crystalline deposits were observed in the ﬁve CKD groups
(Fig. 3B). In addition, on Azan-Mallory staining, each mono-
therapy reduced the severity of renal ﬁbrosis evoked by
adenine administration, and the combination therapy showed a
greater decrease in renal ﬁbrosis than each monotherapy
(Fig. 3C, D).3.5. Effect of CM and/or TE treatment on oxidative stress markers in
the blood and kidney
We examined oxidative stress as a well-known mediator of
kidney disease to clarify the mechanism by which combination
therapy with CM and TE exerts its renoprotective effect. Plasma
AOPP, a marker of protein oxidation, was increased in the CKD
groups, while treatment groups except for the HYD group, had
signiﬁcantly suppressed plasma AOPP (Fig. 4A). Interestingly,
combination therapy markedly reduced plasma AOPP beyond
that of each monotherapy. Similarly, an increase in plasma
TBARS, which is a major lipid peroxide marker, by adenineCM CMþTE HYD
8 6 6
333 ± 19*** 350 ± 15*** 360 ± 15***
59.1 ± 8.2***,# 40.2 ± 3.7***,###,x 72.5 ± 10.2***
72 ± 3.9*** 70 ± 5.7*** 80 ± 5.4***
1.51 ± 0.11***,## 1.23 ± 0.08***,###,y,z,xxx 1.81 ± 0.12***
1.37 ± 0.14*** 1.46 ± 0.18*** 0.92 ± 0.14***
141 ± 1 140 ± 1 143 ± 2
4.6 ± 0.4 5.1 ± 0.3** 5.7 ± 0.3***,z
0.60 ± 0.03** 0.58 ± 0.03* 0.56 ± 0.01*
mostat mesilate, HYD: hydralazine, BW: body weight, KW/BW: kidney weight/body
ium, K: serum potassium, and U-Na/K: urinary sodium-to-potassium ratio. *P < 0.05,
1 compared with CKD group; yP < 0.05 compared with TE group; zP < 0.05, zzP < 0.01
Fig. 2. Macroscopic morphology of kidneys from the six groups. Rat kidneys from the CKD groups show swelling, discoloration, and deformity as compared with those of the
control group. The gross morphologic injury was attenuated by CM and TE respectively, but treatment with CM and TE further improved this condition. Scale bar: 10 mm.
Fig. 3. Kidney histopathology. (A) Representative photomicrographs of PAS stained kidney sections. There were no marked differences among the six groups with respect to their
glomeruli (200). Scale bars: 50 mm. (B) Tubulointerstitial injury was signiﬁcant in the CKD groups relative to the control group (100). Scale bars: 200 mm. (C) Representative
photomicrographs of Azan-Mallory stained kidney sections (100). Scale bars: 200 mm. (D) The interstitial ﬁbrosis areas were evaluated as described in the Materials and methods
section, and the values are summarized in the bar graphs. Results are expressed as means ± SE. ***P < 0.001 compared with the Control group; ###P < 0.001 compared with the
CKD group; xxxP < 0.001 compared with the HYD group.
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therapy in comparison with each monotherapy (Fig. 4B).
Furthermore, DHE staining revealed that the combination
therapy signiﬁcantly reduced the accumulation of ROS relative
to each monotherapy in the tubulointerstitial compartment
(Fig. 4C, D).3.6. Effect of CM and/or TE treatment on mRNA expression and
protein levels of ﬁbrotic markers
Because oxidative stress plays an important role in the devel-
opment and progression of renal ﬁbrosis, we evaluated the effect of
the combination therapy on renal ﬁbrosis by assessing ﬁbrotic
Fig. 4. Antioxidative effect of CM and/or TE treatment. (A) Advanced oxidative protein products (AOPPs) measurements. AOPPs concentrations were determined in the plasma by
the method of Witko-Sarsat, and the values are summarized in the bar graph. (B) Plasma levels of 2-thiobarbituric acid reactive substances (TBARS) measurements. TBARS con-
centrations were measured by using a TBARS assay kit, and the values are summarized in the bar graph. (C) Dihydroethidium (DHE) staining. DHE staining of kidney sections (100)
is shown. Scale bars: 100 mm. Frozen sections were incubated with 0.1 mM DHE, and images were obtained with an Olympus BX50 with BH2-RFL-T3 (Olympus, Tokyo, Japan). (D)
Quantiﬁcation of ﬂuorescence intensity was performed by using Image-J, and the values are summarized in the bar graph. Results are expressed as means ± SE. *P < 0.05, **P < 0.01,
***P < 0.001 compared with the Control group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the CKD group; xxxP < 0.001 compared with the HYD group.
Y. Narita et al. / Journal of Pharmacological Sciences 130 (2016) 110e116114markers such as CTGF, a-SMA, PAI-1, and ﬁbronectin. The mRNA
expression of CTGF was markedly reduced in the combination
therapy relative to each monotherapy (Fig. 5A). The mRNA ex-
pressions of a-SMA and PAI-1 showed a tendency to decrease in the
combination therapy (Fig. 5B, C). Moreover, the protein levels of a-
SMA and ﬁbronectin were signiﬁcantly decreased in the combina-
tion therapy compared to each monotherapy (Fig. 5D, E).3.7. Effect of CM and/or TE treatment on the RAS components
We determined plasma aldosterone concentration (PAC) and
plasma renin activity (PRA) to examine if CM modulates RAS
components to exert its renoprotective effect. The monotherapy
with TE and the combination therapy signiﬁcantly reduced the
adenine-induced elevation of PAC to a similar extent, while the
monotherapy with CM or Hyd had no effect on it (Fig. 6A). Likewise,
the monotherapy with TE and the combination therapy markedly
ameliorated the adenine-induced suppression of PRA to a similar
extent, while the monotherapy with CM and Hyd had no effect on it
(Fig. 6B).4. Discussion
The results in this study demonstrated the effect of a combi-
nation therapy with CM and TE on the progression of CKD in the
adenine-induced rat CKD model. We found that the combination
therapy provided further renoprotection relative to each mono-
therapy (Table 1). The combination therapy resulted in a greater
reduction in oxidative stress and renal ﬁbrosis compared to each
monotherapy and the effect was independent of their blood
pressure-lowering effect (Figs. 1, 4 and 5).According to the ONTARGET study, the combination therapy
with ramipril and telmisartan reduced urinary albumin excretion
but failed to preserve renal function (16). On the other hand,
Shiraishi et al. showed that the combination therapy with enalapril
and nicorandil provided greater renoprotection in a rat CKD model
(17). Namikoshi et al. showed that the combination therapy with
candesartan and pioglitazone enhanced the renoprotective effect in
Zucker obese rats (18). Therefore, it is reasonable to speculate that
combination therapy can provide additional beneﬁt if each medi-
cine shows renoprotective effect through an independent mecha-
nism. Our current study revealed that the combination therapy
with CM and TE resulted in the greater renoprotection than each
monotherapy. As shown in Fig. 6, the effect of the combination
therapy on PAC and PRAwas similar to that of TE monotherapy, and
CM had no effect on both PAC and PRA. These ﬁndings suggest that
the greater renoprotection in the combination therapy was attrib-
uted to a distinct pharmacological property of CM from RAS
inhibition.
Although both CM and TE have been demonstrated to have an
anti-oxidant activity by suppressing the NADPH oxidase component
(19e21), the combination therapy with CM and TE showed further
reduction in oxidative stress than each monotherapy in our current
study. We speculated that this additive anti-oxidant effect of CM is
partly due to its direct radical scavenging activity against hydroxyl
radical (12). Previously, we demonstrated that CM inhibited the TGF-
b1 signaling in renal ﬁbroblasts and subsequently suppressed the
progression of renal ﬁbrosis (11). RAS inhibiters have been shown to
reduce the production of TGF-b1 and subsequently suppress the
progression of renal ﬁbrosis (22, 23). Because CM and TE reduced
renal ﬁbrosis through a different mechanism, the combination
therapy could result in a greater decrease in renal ﬁbrosis than each
monotherapy. In addition, since the oxidative stress is one of the
Fig. 5. Antiﬁbrotic effect of CM and/or TE treatment. mRNA expressions of connective tissue growth factor (CTGF) (A), a-SMA (B), and plasminogen activator inhibitor-1 (PAI-1)
(C) were determined by the real-time PCR. Expression of mRNA was normalized by 28S ribosomal RNA, and values are expressed as fold increase over the control group. Protein
levels of a-smooth muscle actin (a-SMA) (D), ﬁbronectin (E) and GAPDH were evaluated by immunoblot analysis. Densitometry values of a-SMA and ﬁbronectin were normalized by
GAPDH. Values are expressed as fold increases over the control group and shown in the bar graphs. Results are expressed as means ± SE. *P < 0.05, **P < 0.01, ***P < 0.001 compared
with the Control group; ##P < 0.01, ###P < 0.001 compared with the CKD group; xxP < 0.01, xxxP < 0.001 compared with the HYD group.
Fig. 6. Effect of CM and/or TE treatment on plasma aldosterone concentration and plasma renin activity. At the end of the study period, blood samples were collected from the abdominal
aorta. Plasma aldosterone concentration (A) and plasma renin activity (B) were determined. Results are expressed as means ± SE. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the Control
group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the CKD group; yP < 0.05, yyP < 0.01 compared with TE group; xxP < 0.01, xxxP < 0.001 compared with HYD group.
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greater reduction in renal ﬁbrosis in the combination therapy could
be attributed to the further reduction in oxidative stress. In the
current investigations, we were unable to determine the detailed
mechanisms by which CM exerts its renoprotective effect. However,
this is the ﬁrst report showing the effect of combination therapywith
CM and a RAS inhibitor on the progression of CKD.
In conclusion, the combination therapy with CM and TE pro-
vided further renoprotective effect than each monotherapy
through the greater reduction in oxidative stress and renal ﬁbrosis
in an adenine-induced rat CKD model. Our present results suggest
that CM could be a candidate drug for an add-on therapy for CKD
patients who had been treated with RAS inhibitors.Acknowledgment
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